CMV (Cytomegalovirus)



Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus Vaccines mRNA-1647 and mRNA-1443 in Healthy Adults


Condition:   Cytomegalovirus Infection
Interventions:   Biological: mRNA-1647;   Biological: mRNA-1443;   Other: Placebo
Sponsor:   Moderna Therapeutics
Recruiting


Asymptomatic Congenital CMV Treatment


Condition:   Congenital Cytomegalovirus Infection
Intervention:   Drug: Valganciclovir
Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting


Virus Specific Cytotoxic T-Lymphocytes (CTLs) for Refractory Cytomegalovirus (CMV)


Conditions:   Cytomegalovirus Infections;   Primary Immune Deficiency Disorder
Intervention:   Drug: viral specific cytotoxic t-lymphocytes
Sponsors:   New York Medical College;   Children's Hospital of Philadelphia;   Medical College of Wisconsin
Not yet recruiting


Biomarkers of Cytomegalovirus Fetal Infection and Disease


Condition:   Cytomegalovirus Congenital
Intervention:   Biological: Bio-specimen collected
Sponsor:   Assistance Publique - Hôpitaux de Paris
Recruiting


Efficacy and Safety of Maribavir in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment


Condition:   Cytomegalovirus (CMV)
Interventions:   Drug: Maribavir;   Drug: Investigator-Assigned Treatment
Sponsor:   Shire
Recruiting


Study for the Treatment of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant Recipients


Condition:   Cytomegalovirus (CMV)
Interventions:   Drug: Maribavir;   Drug: Valganciclovir;   Drug: Placebo
Sponsor:   Shire
Recruiting


Study to Evaluate Safety, Tolerability, and Immunogenicity of Candidate Human Cytomegalovirus Vaccine in Healthy Adults


Condition:   Cytomegalovirus Infections
Interventions:   Drug: VBI-1501A;   Drug: VBI-1501;   Drug: Placebo
Sponsors:   VBI Vaccines Inc.;   Clinical Trial Data Services, LLC;   Virginia Commonwealth University
Completed


Trial to Evaluate Safety and Immunogenicity of a Vaccine Against HCMV


Condition:   Cytomegalovirus Infection
Interventions:   Biological: Low dose HB-101;   Biological: Medium dose HB-101;   Biological: High dose HB-101;   Biological: Placebo
Sponsors:   Hookipa Biotech;   Centre for Vaccinology Ghent - CEVAC
Active, not recruiting


Assesment of Olfactory Disorders and Performance of a New Olfactory Test in Children With Congenital CMV


Condition:   Congenital Cytomegalovirus Infection
Intervention:   Other: olfactory tests, otoacoustic emissions (OAE)
Sponsor:   Institut Pasteur
Recruiting


Screening for Congenital Cytomegalovirus Infection in Newborns


Condition:   Cytomegalovirus Infections
Intervention:   Other: Observation
Sponsors:   Southern Illinois University;   University of Alabama at Birmingham
Enrolling by invitation


Prevalence of Cytomegalovirus Infection in Patients With Quiescent Ulcerative Colitis


Conditions:   Ulcerative Colitis;   Cytomegalovirus Infections
Intervention:  
Sponsor:   University of British Columbia
Recruiting


A Cohort Study of Cytomegalovirus(CMV) Infection Among Pregnant Women and Their Newborns in China


Conditions:   Congenital Cytomegalovirus Infection;   Cytomegalovirus Infection Reactivation
Intervention:  
Sponsors:   Jun Zhang;   Merck Sharp & Dohme Corp.;   National Natural Science Foundation of China
Recruiting


Valacyclovir to Prevent Vertical Transmission of Cytomegalovirus After Maternal Primary Infection During Pregnancy


Condition:   Congenital Cytomegalovirus Infection
Interventions:   Drug: Valacyclovir;   Drug: Placebo
Sponsor:   Rabin Medical Center
Recruiting


Safety, Tolerability, and Immunogenicity of the Human Cytomegalovirus Vaccine (V160) in Healthy Adults (V160-001)


Condition:   Cytomegalovirus Infections
Interventions:   Biological: V160 Low Dose IM;   Biological: V160 Medium Dose IM;   Biological: V160 High Dose IM;   Biological: V160 Medium Dose plus Merck Aluminum Phosphate Adjuvant (MAPA) 225 µg /dose IM;   Biological: V160 High Dose plus MAPA 225 µg /dose IM;   Biological: V160 Maximum Dose IM;   Other: Placebo IM;   Biological: V160 Medium Dose ID;   Other: Placebo ID
Sponsor:   Merck Sharp & Dohme Corp.
Completed


A Study to Evaluate the Efficacy and Safety of a Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seronegative Kidney Transplant Recipients Receiving an Organ From a CMV-Seropositive Donor


Condition:   Kidney Transplantation Cytomegalovirus (CMV) Negative Recipients
Interventions:   Biological: ASP0113;   Drug: Placebo
Sponsors:   Astellas Pharma Global Development, Inc.;   Vical
Active, not recruiting


A Study to Evaluate a Therapeutic Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seropositive Recipients Undergoing Allogeneic, Hematopoietic Cell Transplant (HCT)


Conditions:   Cytomegalovirus (CMV)-Positive Recipients;   Allogeneic, Hematopoietic Cell Transplant (HCT)
Interventions:   Biological: ASP0113;   Drug: Placebo
Sponsors:   Astellas Pharma Global Development, Inc.;   Vical
Active, not recruiting


A Study of MCMV5322A/MCMV3068A for the Prevention of Cytomegalovirus Disease in High-Risk Kidney Allograft Recipients


Condition:   Cytomegalovirus Infections
Interventions:   Drug: MCMV3068A;   Drug: MCMV5322A;   Drug: Placebo
Sponsor:   Genentech, Inc.
Completed


A Study in Adolescent Females to Explore Cytomegalovirus Infection


Condition:   Infections, Cytomegalovirus
Interventions:   Procedure: Blood collection;   Procedure: Urine collection;   Procedure: Saliva collection
Sponsor:   GlaxoSmithKline
Completed


Evaluation of the PK and PD of Ganciclovir in Premature Infants Receiving Treatment for CMV Infection


Condition:   Cytomegalovirus Infections
Intervention:  
Sponsor:   University of Alabama at Birmingham
Recruiting


A Randomized Trial to Prevent Congenital Cytomegalovirus (CMV)


Conditions:   Congenital Cytomegalovirus Infection;   Maternal Cytomegalovirus Infection
Interventions:   Drug: CMV hyperimmune globulin;   Other: Placebo
Sponsors:   The George Washington University Biostatistics Center;   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting


Evaluation of the Long-term Persistence of GlaxoSmithKline (GSK) Biologicals' Candidate Cytomegalovirus (CMV) Vaccine


Condition:   Infections, Cytomegalovirus
Interventions:   Procedure: Blood sampling;   Biological: GSK149203A
Sponsor:   GlaxoSmithKline
Completed


Study of the Transmission of Cytomegalovirus (CMV) Infection From Mother to Foetus


Condition:   Infections, Cytomegalovirus
Interventions:   Procedure: Blood sample;   Procedure: Cord blood sample;   Procedure: Saliva swab;   Procedure: Urine sampling;   Procedure: Vaginal swab
Sponsor:   GlaxoSmithKline
Completed


Cytomegalovirus (CMV) Specific Cytotoxic T Lymphocytes (CTL) When Used for Prophylaxis Against CMV in Recipients of Allogeneic, T Cell Depleted Stem Cell Transplants


Condition:   Cytomegalovirus Infections
Intervention:   Biological: CMV Specific Cytotoxic T Lymphocytes
Sponsor:   Milton S. Hershey Medical Center
Completed


Trial of Donor T Cells Sensitized With Pentadecapeptides of the CMV-PP65 Protein for the Treatment of Cytomegalovirus (CMV) Infections Following Allogeneic Hematopoietic Stem Cell Transplants


Condition:   Cytomegalovirus Infections
Intervention:   Biological: CMV-Peptide-Specific T cells
Sponsors:   Atara Biotherapeutics;   Memorial Sloan Kettering Cancer Center
Completed


gB/MF59 Vaccine in Preventing Cytomegalovirus Infection in Healthy Adolescent Females


Condition:   Cytomegalovirus Infections
Interventions:   Biological: MF-59;   Drug: Placebo;   Biological: CMV gB vaccine
Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
Completed

Refine Your Search Advanced Search